Pharmaceuticals News

Bagsværd, Denmark, 16 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...

Jennings-Brown will drive AI and technology strategy and lead the development of capabilities enabling discovery of therapeutics targeting fundamental aging mechanisms Offices in Abu Dhabi's premier...

CAMBRIDGE, United Kingdom, Feb. 16, 2026 (GLOBE NEWSWIRE) -- LEX Diagnostics, a leading innovator in molecular diagnostics, has received U.S. Food and Drug Administration (FDA) 510(k) clearance and...

        HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1, a genetically validated target in Huntington’s disease Clinical Advisory Board...

Communiqué de presseNicox annonce une réunion pré-NDA positive avec la FDA américaine pour NCX 470  Le dépôt de la demande d’autorisation de mise sur le marché (NDA) aux Etats-Unis reste prévu pour...

Press Release Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470 U.S. NDA submission on track for summer 2026Nicox to receive milestone payment from Kowa upon submission...

L’étude sur Beyfortus publiée dans la revue The Lancet Infectious Diseases montre ses bénéfices chez les nourrissons au-delà de la première saison du VRS La première étude montre que les nourrissons...

Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season First study showing that infants immunized against RSV in their first season had fewer...

MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years Up to 30% of people with membranous nephropathy progress to...

加利福尼亚州圣迭戈, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Sapu Bioscience 今日宣布支持 OT-101 （公司专有的 TGF-β 反义治疗平台）的全球知识产权组合取得了进展，进一步强化了该平台在神经学、肿瘤学及中枢神经系统药物递送领域的保护范围。 OT-101 背景介绍 OT-101（TGF-β...